Mild to moderate dementia: Symptomatic and neuroprotective

T2 Protect AD ( Sponsored by Biohaven and the NIA-funded Alzheimer’s Disease Cooperative Study at UCSD. This is a study of troriluzole, a glutamate modulator that may slow progression of AD or enhance cognition. This is a 48-week RPCT trial. Ages 50-85, MMSE=14-24. May be on AChEI or memantine. Primary outcome is ADAS-Cog 11. Secondary measures are CDR-SOB, volumetric MRI and a neuropsychological test battery. CSF biomarkers and genotype are also measured.